The global home care testing market size was valued at USD 9.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 9.3% from 2023 to 2030.The growth of the market is being driven by various factors, such as the rising incidence of chronic diseases such as diabetes, cardiovascular diseases, and respiratory diseases, growing demand for point-of-care testing, an aging population, and technological advancements. According to the data published by WHO, by the year 2030, one out of every six individuals globally will be aged 60 years or above. This demographic will grow from 1 billion in 2020 to 1.4 billion, leading to a significant increase in the proportion of people aged 60 and above. By the year 2050, the number of individuals aged 60 years and above is expected to double to 2.1 billion, indicating a rapid demographic shift.
As the population ages, the demand for healthcare services would also increase. Older adults are more likely to have chronic conditions that require frequent monitoring, making home care testing devices a valuable tool for managing their health.The COVID-19 pandemic has increased the demand for home care testing kits, especially for COVID-19 testing kits, as patients avoided exposure to the virus by reducing their visits to healthcare facilities. The COVID-19 test from home has become increasingly popular, especially during the pandemic.
This trend has boosted the demand for home care testing, such as rapid antigen tests, antibody tests, and PCR tests. The demand has been further fueled by the need for regular testing among individuals who are at high risk of contracting the virus, such as healthcare workers and those who have been in close contact with the infected individuals. Emerging innovations in home healthcare are seen as a potential solution to the gap between demand and supply.
Testing, consultations with doctors, and high-quality patient care can now all be easily provided to patients at their homes. These developments have made it possible for patients to manage their conditions more conveniently and efficiently.They no longer have to travel to healthcare facilities, which is particularly beneficial for those who live in rural or remote areas. The availability of home care testing and consultations with doctors has also increased access to healthcare services, which have the potential to improve health outcomes for patients.
Based on age, the geriatric segment accounted for the largest market share of 56.54% in 2022 and is projected to continue to dominate the market over the forecast period. According to the NCBIdata, the U.S. is expected to see a significant increase of 61.11% in the number of individuals aged 50 years and older, rising from 137.25 million in 2020 to 221.13 million in 2050. Along with this, the population aged 50 years and older is projected to see a surge in the number of individuals who have at least one chronic disease. This is expected to increase by 99.5%, rising from 71.522 million in 2020 to 142.66 million in 2050.
These factors would further increase the demand for homecare testing kits in the coming years.The pediatric segment is anticipated to register lucrative growth during the forecast period. Home care testing can improve outcomes for pediatric patients by allowing for more frequent monitoring and earlier detection of changes in health status. Moreover, advancements in neonatal care have led to lower infant mortality rates, and premature infants, as well as babies with life-limiting birth defects or chronic illnesses, have a greater chance of survival. These factors have increased the demand for pediatric home care services.
The urine sample segment dominated the market in 2022 and accounted for the largest share of 36.62% of the global revenue and is anticipated to grow at the fastest growth rate over the forecast period. Urine sample collection is a non-invasive and easy process, which can be performed at home. Advances in technology have led to more accurate and reliable urine sample testing, allowing for earlier detection and treatment of health conditions. In January 2023, Withings, a company pioneering in connected health, announced the launch of an in-home biomarker analysis platform, U-Scan.
It is a miniaturized health lab that can be placed inside any toilet bowl to analyze urine samples and provide users with real-time health information. It detects a wide range of health conditions, such as urinary tract infections, kidney disease, and even some types of cancer.Furthermore, the blood sample segment is expected to grow at a substantial CAGR during the forecast period. Blood sample testing can be used to detect several health conditions, including diabetes, heart disease, and several other infections. This makes it a widely used diagnostic tool in the healthcare industry. It is a convenient and cost-effective way to monitor the patient’s health and diagnose medical conditions.
The infectious disease test segment witnessed considerable market growth in 2022 and accounted for a share of 18.70% of the global revenue. Homecare testing for infectious diseases has become an essential tool after the COVID-19 pandemic on account of convenience and accessibility, as many people were hesitant to visit hospitals or clinics due to the fear of exposure to the virus. Homecare testing for COVID-19 was crucial to control the spread of the virus, especially in areas with high infection rates. In February 2023, the FDA authorized the first over-the-counter at-home test to detect COVID-19 and influenza viruses.
Furthermore, the diabetes and glucose tests segment are expected to grow at substantial CAGRs during the forecast period. Diabetes is a chronic condition that affects millions of people worldwide, and glucose testing is a key part of managing diabetes. Home care testing kits for glucose monitoring are widely available, and they allow patients to test their blood sugar levels at home using a simple finger prick. In April 2023, the world-first pilot program, conducted by a hospital trust in the UK, allows pregnant women to take the glucose tolerance test at home using a home care testing kit. Continuous advancements in this field would further drive the segment’s growth.
The retail pharmacies segment dominated the market in 2022 and accounted for the largest share of 49.70% of the global revenue. These are easily accessible to consumers, with many located in convenient locations, such as shopping centers and grocery stores. This makes it easy for consumers to purchase home care testing kits or pick up test results. Moreover, retail pharmacies have a wide range of home care testing products available, such as tests for blood glucose, cholesterol, pregnancy, and infectious diseases, such as HIV and hepatitis.
This allows consumers to choose the tests that best suit their needs, thus increasing the demand for home care testing.Furthermore, the online pharmacies segment is expected to grow at a substantial CAGR during the forecast period. The growth of the market is attributed to factors, such as ease of convenience, availability of a wide range of products, competitive pricing, privacy, and accessibility. Online pharmacies offer competitive pricing for home care testing products, which can be more affordable than purchasing them from a physical retail pharmacy. This could be one of the factors driving the segment’s growth.
The strip segment dominated the market in 2022 and accounted for the largest share of 28.31% of the global revenue. The striptests are relatively inexpensive and easy to use and can be performed at home without the need for specialized equipment or laboratory analysis, making them ideal for self-monitoring and early detection of health conditions. These are also portable, making them ideal for use in resource-limited settings and for mobile healthcare applications. In June 2020, chemists from Iowa State University announced of developing paper-strip urine tests for COVID-19. It is a non-invasive and convenient method for individuals to test for the virus at home.
The cassette segment is expected to grow at a substantial CAGR during the forecast period. These tests are designed simple and easy to use, producing results in less than a minute. In addition, cassette tests are more sensitive and specific than strip tests, making them ideal for detecting low levels of analytes. In October 2021, Intrivo announced the launch of an FDA-authorized at-home rapid COVID-19 self-test, Intrivo’s On/Go. The test delivers 95% accuracy within 10 minutes, making it a reliable and convenient way for individuals to test themselves for COVID-19 in the comfort of their own homes.
North America held the largest share of 32.40% in 2022. The region has a highly developed healthcare system, which has led to higher investment in research and development of home care testing. Moreover, the availability of a wide range of home care testing products, such as rapid diagnostic tests, self-monitoring devices, and mobile health apps is also contributing to the regional market growth. In addition, a supportive regulatory framework is also driving the market growth.
For instance, the FDA in the U.S. and Health Canada in Canada have established clear regulatory pathways for home care testing products, which has enabled faster approval and commercialization of new products.Asia Pacific is projected to witness the fastest growth rate during the forecast period.The growth of the market is attributed to the growing elderly population, the increasing prevalence of chronic diseases, such as diabetes, cardiovascular disease, and cancer, in the region. Several government initiatives, technological advancements, and increasing awareness & acceptance of home care testing products are also contributing to the regional market growth.
The global market is highly fragmented.Major players focus on growth strategies, such as new product launches, collaborations, partnerships, expansion, and mergers & acquisitions. For instance, in February 2023, R.R. Donnelley & Sons Company (RRD) expanded its diagnostic test kit solution to meet the growing demand for at-home testing. The COVID-19 pandemic has boosted the demand for at-home testing, and RRD's expansion of its diagnostic test kit solution aims to help meet this demand.
In January 2023, The National Institutes of Health (NIH) launched a pilot program called Home Test to Treat in response to the COVID-19 pandemic. The program aims to provide patients with at-home COVID-19 testing kits and telehealth services to help manage their symptoms and provide guidance on how to best care for themselves while in isolation.Some of the prominent players in the global home care testing market include:
Abbott
BD
Quidel Corp.
BioSure
F. Hoffmann-La Roche Ltd.
Nova Biomedical
Siemens Healthcare GmbH
ACON Laboratories, Inc.
OraSure Technologies, Inc.
Chembio Diagnostics, Inc.
Report Attribute |
Details |
Market size value in 2023 |
USD 9.85 billion |
Revenue forecast in 2030 |
USD 18.30 billion |
Growth rate |
CAGR of 9.3% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD Million/Billion and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Age, sample, test type, distribution channel, product, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Abbott; BD; Quidel Corp.; BioSure; F. Hoffmann-La Roche Ltd.; Nova Biomedical; Siemens Healthcare GmbH; ACON Laboratories, Inc.; OraSure Technologies, Inc.; Chembio Diagnostics, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global home care testing market based on age, sample, test type, distribution channel, product, and region:
Age Outlook (Revenue, USD Million, 2018 - 2030)
Pediatric
Adult
Geriatric
Sample Outlook (Revenue, USD Million, 2018 - 2030)
Urine
Saliva
Blood
Others
Test Type Outlook (Revenue, USD Million, 2018 - 2030)
HIV Test Kit
Diabetes and Glucose Tests
Cholesterol and Triglycerides Tests
Pregnancy Tests
Infectious Diseases Tests
Urinary Tract Infection Tests
Others
Distribution channel Outlook (Revenue, USD Million, 2018 - 2030)
Retail Pharmacies
Supermarket/Hypermarket
Online Pharmacies
Product Outlook (Revenue, USD Million, 2018 - 2030)
Strip
Cassette
Test Panel
Midstream
Dip Card
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global home care testing market size was estimated at USD 9.05 billion in 2022 and is expected to reach USD 9.84 billion in 2030.
b. The global home care testing market is expected to grow at a compound annual growth rate of 9.3% from 2022 to 2030 to reach USD 18.29 billion by 2030.
b. North America dominated the home care testing market with a share of 32.4% in 2022. This is attributable to increasing number of product launches and ease of use for home care testing devices.
b. Some key players operating in the home care testing market include Abbott, BD,Quidel Corporation, BioSure, F. Hoffmann-La Roche Ltd., Nova Biomedical, Siemens Healthcare GmbH, ACON Laboratories, Inc., OraSure Technologies, Inc., and Chembio Diagnostics, Inc.
b. Key factors that are driving the market growth include increase in chronic disorders prevalence and the increase in the adoption of testing kits for disorder diagnosis.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."